Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT)...

Authors :: De Giorgi, Ugo
Azad, Arun
Fizazi, Karim
Matsubara, Nobuaki
Saad, Fred
Joung, Jae Young
Fong, Peter C.C.
Jones, Robert J.
Zschaebitz, Stefanie
Oldenburg, Jan
Shore, Neal D.
Dunshee, Curtis
Carles, Joan
Fay, Andre P.
Cislo, Paul
Kirker, Melissa
Healy, Cynthia G.
Niyazov, Alexander
Agarwal, Neeraj
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p116-116, 235p
Publication Year :: 2024

Full Text Access

Tools